The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Spinal Muscular Atrophy Medicine-Global Market Insights and Sales Trends 2025
Synopsis
The global Spinal Muscular Atrophy Medicine market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Spinal Muscular Atrophy Medicine in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Spinal Muscular Atrophy Medicine market. LMI-070, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the ND-602 segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Spinal Muscular Atrophy Medicine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Spinal Muscular Atrophy Medicine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Spinal Muscular Atrophy Medicine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Spinal Muscular Atrophy Medicine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Spinal Muscular Atrophy Medicine covered in this report include Astellas Pharma Inc., AveXis, Inc., Bioblast Pharma Ltd., Cytokinetics, Inc. 24, F. Hoffmann-La Roche Ltd., Genethon, Genzyme Corporation, GMP-Orphan SAS and Ionis Pharmaceuticals, Inc., etc.
The global Spinal Muscular Atrophy Medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astellas Pharma Inc.
AveXis, Inc.
Bioblast Pharma Ltd.
Cytokinetics, Inc. 24
F. Hoffmann-La Roche Ltd.
Genethon
Genzyme Corporation
GMP-Orphan SAS
Ionis Pharmaceuticals, Inc.
Longevity Biotech, Inc
Neurodyn Inc.
Neurotune AG
Novartis AG
Sarepta Therapeutics, Inc.
Voyager Therapeutics, Inc.
Vybion, Inc.
WAVE Life Sciences Ltd.
Global Spinal Muscular Atrophy Medicine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Spinal Muscular Atrophy Medicine market, Segment by Type:
LMI-070
ND-602
NT-1654
Nusinersen
NXD-30001
Others
Global Spinal Muscular Atrophy Medicine market, by Application
Hospital
Clinic
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Spinal Muscular Atrophy Medicine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Spinal Muscular Atrophy Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
The global Spinal Muscular Atrophy Medicine market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Spinal Muscular Atrophy Medicine in various end use industries. The expanding demands from the Hospital, Clinic and Others,, are propelling Spinal Muscular Atrophy Medicine market. LMI-070, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the ND-602 segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Spinal Muscular Atrophy Medicine, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Spinal Muscular Atrophy Medicine market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Spinal Muscular Atrophy Medicine market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Spinal Muscular Atrophy Medicine sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Spinal Muscular Atrophy Medicine covered in this report include Astellas Pharma Inc., AveXis, Inc., Bioblast Pharma Ltd., Cytokinetics, Inc. 24, F. Hoffmann-La Roche Ltd., Genethon, Genzyme Corporation, GMP-Orphan SAS and Ionis Pharmaceuticals, Inc., etc.
The global Spinal Muscular Atrophy Medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Astellas Pharma Inc.
AveXis, Inc.
Bioblast Pharma Ltd.
Cytokinetics, Inc. 24
F. Hoffmann-La Roche Ltd.
Genethon
Genzyme Corporation
GMP-Orphan SAS
Ionis Pharmaceuticals, Inc.
Longevity Biotech, Inc
Neurodyn Inc.
Neurotune AG
Novartis AG
Sarepta Therapeutics, Inc.
Voyager Therapeutics, Inc.
Vybion, Inc.
WAVE Life Sciences Ltd.
Global Spinal Muscular Atrophy Medicine market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Spinal Muscular Atrophy Medicine market, Segment by Type:
LMI-070
ND-602
NT-1654
Nusinersen
NXD-30001
Others
Global Spinal Muscular Atrophy Medicine market, by Application
Hospital
Clinic
Others
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Spinal Muscular Atrophy Medicine manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Spinal Muscular Atrophy Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Spinal Muscular Atrophy Medicine Market Overview
1.1 Spinal Muscular Atrophy Medicine Product Overview
1.2 Spinal Muscular Atrophy Medicine Market Segment by Type
1.2.1 LMI-070
1.2.2 ND-602
1.2.3 NT-1654
1.2.4 Nusinersen
1.2.5 NXD-30001
1.2.6 Others
1.3 Global Spinal Muscular Atrophy Medicine Market Size by Type
1.3.1 Global Spinal Muscular Atrophy Medicine Market Size Overview by Type (2018-2029)
1.3.2 Global Spinal Muscular Atrophy Medicine Historic Market Size Review by Type (2018-2023)
1.3.3 Global Spinal Muscular Atrophy Medicine Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2018-2023)
1.4.2 Europe Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Spinal Muscular Atrophy Medicine Sales Breakdown by Type (2018-2023)
2 Global Spinal Muscular Atrophy Medicine Market Competition by Company
2.1 Global Top Players by Spinal Muscular Atrophy Medicine Sales (2018-2023)
2.2 Global Top Players by Spinal Muscular Atrophy Medicine Revenue (2018-2023)
2.3 Global Top Players by Spinal Muscular Atrophy Medicine Price (2018-2023)
2.4 Global Top Manufacturers Spinal Muscular Atrophy Medicine Manufacturing Base Distribution, Sales Area, Product Type
2.5 Spinal Muscular Atrophy Medicine Market Competitive Situation and Trends
2.5.1 Spinal Muscular Atrophy Medicine Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Spinal Muscular Atrophy Medicine Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Spinal Muscular Atrophy Medicine as of 2022)
2.7 Date of Key Manufacturers Enter into Spinal Muscular Atrophy Medicine Market
2.8 Key Manufacturers Spinal Muscular Atrophy Medicine Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Spinal Muscular Atrophy Medicine Status and Outlook by Region
3.1 Global Spinal Muscular Atrophy Medicine Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Spinal Muscular Atrophy Medicine Historic Market Size by Region
3.2.1 Global Spinal Muscular Atrophy Medicine Sales in Volume by Region (2018-2023)
3.2.2 Global Spinal Muscular Atrophy Medicine Sales in Value by Region (2018-2023)
3.2.3 Global Spinal Muscular Atrophy Medicine Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Spinal Muscular Atrophy Medicine Forecasted Market Size by Region
3.3.1 Global Spinal Muscular Atrophy Medicine Sales in Volume by Region (2024-2029)
3.3.2 Global Spinal Muscular Atrophy Medicine Sales in Value by Region (2024-2029)
3.3.3 Global Spinal Muscular Atrophy Medicine Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Spinal Muscular Atrophy Medicine by Application
4.1 Spinal Muscular Atrophy Medicine Market Segment by Application
4.1.1 Hospital
4.1.2 Clinic
4.1.3 Others
4.2 Global Spinal Muscular Atrophy Medicine Market Size by Application
4.2.1 Global Spinal Muscular Atrophy Medicine Market Size Overview by Application (2018-2029)
4.2.2 Global Spinal Muscular Atrophy Medicine Historic Market Size Review by Application (2018-2023)
4.2.3 Global Spinal Muscular Atrophy Medicine Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2018-2023)
4.3.2 Europe Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Spinal Muscular Atrophy Medicine Sales Breakdown by Application (2018-2023)
5 North America Spinal Muscular Atrophy Medicine by Country
5.1 North America Spinal Muscular Atrophy Medicine Historic Market Size by Country
5.1.1 North America Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Spinal Muscular Atrophy Medicine Sales in Volume by Country (2018-2023)
5.1.3 North America Spinal Muscular Atrophy Medicine Sales in Value by Country (2018-2023)
5.2 North America Spinal Muscular Atrophy Medicine Forecasted Market Size by Country
5.2.1 North America Spinal Muscular Atrophy Medicine Sales in Volume by Country (2024-2029)
5.2.2 North America Spinal Muscular Atrophy Medicine Sales in Value by Country (2024-2029)
6 Europe Spinal Muscular Atrophy Medicine by Country
6.1 Europe Spinal Muscular Atrophy Medicine Historic Market Size by Country
6.1.1 Europe Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Spinal Muscular Atrophy Medicine Sales in Volume by Country (2018-2023)
6.1.3 Europe Spinal Muscular Atrophy Medicine Sales in Value by Country (2018-2023)
6.2 Europe Spinal Muscular Atrophy Medicine Forecasted Market Size by Country
6.2.1 Europe Spinal Muscular Atrophy Medicine Sales in Volume by Country (2024-2029)
6.2.2 Europe Spinal Muscular Atrophy Medicine Sales in Value by Country (2024-2029)
7 Asia-Pacific Spinal Muscular Atrophy Medicine by Region
7.1 Asia-Pacific Spinal Muscular Atrophy Medicine Historic Market Size by Region
7.1.1 Asia-Pacific Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Spinal Muscular Atrophy Medicine Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Spinal Muscular Atrophy Medicine Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Spinal Muscular Atrophy Medicine Forecasted Market Size by Region
7.2.1 Asia-Pacific Spinal Muscular Atrophy Medicine Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Spinal Muscular Atrophy Medicine Sales in Value by Region (2024-2029)
8 Latin America Spinal Muscular Atrophy Medicine by Country
8.1 Latin America Spinal Muscular Atrophy Medicine Historic Market Size by Country
8.1.1 Latin America Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Spinal Muscular Atrophy Medicine Sales in Volume by Country (2018-2023)
8.1.3 Latin America Spinal Muscular Atrophy Medicine Sales in Value by Country (2018-2023)
8.2 Latin America Spinal Muscular Atrophy Medicine Forecasted Market Size by Country
8.2.1 Latin America Spinal Muscular Atrophy Medicine Sales in Volume by Country (2024-2029)
8.2.2 Latin America Spinal Muscular Atrophy Medicine Sales in Value by Country (2024-2029)
9 Middle East and Africa Spinal Muscular Atrophy Medicine by Country
9.1 Middle East and Africa Spinal Muscular Atrophy Medicine Historic Market Size by Country
9.1.1 Middle East and Africa Spinal Muscular Atrophy Medicine Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Spinal Muscular Atrophy Medicine Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Spinal Muscular Atrophy Medicine Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Spinal Muscular Atrophy Medicine Forecasted Market Size by Country
9.2.1 Middle East and Africa Spinal Muscular Atrophy Medicine Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Spinal Muscular Atrophy Medicine Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Astellas Pharma Inc.
10.1.1 Astellas Pharma Inc. Company Information
10.1.2 Astellas Pharma Inc. Introduction and Business Overview
10.1.3 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Astellas Pharma Inc. Spinal Muscular Atrophy Medicine Products Offered
10.1.5 Astellas Pharma Inc. Recent Development
10.2 AveXis, Inc.
10.2.1 AveXis, Inc. Company Information
10.2.2 AveXis, Inc. Introduction and Business Overview
10.2.3 AveXis, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.2.4 AveXis, Inc. Spinal Muscular Atrophy Medicine Products Offered
10.2.5 AveXis, Inc. Recent Development
10.3 Bioblast Pharma Ltd.
10.3.1 Bioblast Pharma Ltd. Company Information
10.3.2 Bioblast Pharma Ltd. Introduction and Business Overview
10.3.3 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Bioblast Pharma Ltd. Spinal Muscular Atrophy Medicine Products Offered
10.3.5 Bioblast Pharma Ltd. Recent Development
10.4 Cytokinetics, Inc. 24
10.4.1 Cytokinetics, Inc. 24 Company Information
10.4.2 Cytokinetics, Inc. 24 Introduction and Business Overview
10.4.3 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Cytokinetics, Inc. 24 Spinal Muscular Atrophy Medicine Products Offered
10.4.5 Cytokinetics, Inc. 24 Recent Development
10.5 F. Hoffmann-La Roche Ltd.
10.5.1 F. Hoffmann-La Roche Ltd. Company Information
10.5.2 F. Hoffmann-La Roche Ltd. Introduction and Business Overview
10.5.3 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.5.4 F. Hoffmann-La Roche Ltd. Spinal Muscular Atrophy Medicine Products Offered
10.5.5 F. Hoffmann-La Roche Ltd. Recent Development
10.6 Genethon
10.6.1 Genethon Company Information
10.6.2 Genethon Introduction and Business Overview
10.6.3 Genethon Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Genethon Spinal Muscular Atrophy Medicine Products Offered
10.6.5 Genethon Recent Development
10.7 Genzyme Corporation
10.7.1 Genzyme Corporation Company Information
10.7.2 Genzyme Corporation Introduction and Business Overview
10.7.3 Genzyme Corporation Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Genzyme Corporation Spinal Muscular Atrophy Medicine Products Offered
10.7.5 Genzyme Corporation Recent Development
10.8 GMP-Orphan SAS
10.8.1 GMP-Orphan SAS Company Information
10.8.2 GMP-Orphan SAS Introduction and Business Overview
10.8.3 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.8.4 GMP-Orphan SAS Spinal Muscular Atrophy Medicine Products Offered
10.8.5 GMP-Orphan SAS Recent Development
10.9 Ionis Pharmaceuticals, Inc.
10.9.1 Ionis Pharmaceuticals, Inc. Company Information
10.9.2 Ionis Pharmaceuticals, Inc. Introduction and Business Overview
10.9.3 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Ionis Pharmaceuticals, Inc. Spinal Muscular Atrophy Medicine Products Offered
10.9.5 Ionis Pharmaceuticals, Inc. Recent Development
10.10 Longevity Biotech, Inc
10.10.1 Longevity Biotech, Inc Company Information
10.10.2 Longevity Biotech, Inc Introduction and Business Overview
10.10.3 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Longevity Biotech, Inc Spinal Muscular Atrophy Medicine Products Offered
10.10.5 Longevity Biotech, Inc Recent Development
10.11 Neurodyn Inc.
10.11.1 Neurodyn Inc. Company Information
10.11.2 Neurodyn Inc. Introduction and Business Overview
10.11.3 Neurodyn Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Neurodyn Inc. Spinal Muscular Atrophy Medicine Products Offered
10.11.5 Neurodyn Inc. Recent Development
10.12 Neurotune AG
10.12.1 Neurotune AG Company Information
10.12.2 Neurotune AG Introduction and Business Overview
10.12.3 Neurotune AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Neurotune AG Spinal Muscular Atrophy Medicine Products Offered
10.12.5 Neurotune AG Recent Development
10.13 Novartis AG
10.13.1 Novartis AG Company Information
10.13.2 Novartis AG Introduction and Business Overview
10.13.3 Novartis AG Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.13.4 Novartis AG Spinal Muscular Atrophy Medicine Products Offered
10.13.5 Novartis AG Recent Development
10.14 Sarepta Therapeutics, Inc.
10.14.1 Sarepta Therapeutics, Inc. Company Information
10.14.2 Sarepta Therapeutics, Inc. Introduction and Business Overview
10.14.3 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.14.4 Sarepta Therapeutics, Inc. Spinal Muscular Atrophy Medicine Products Offered
10.14.5 Sarepta Therapeutics, Inc. Recent Development
10.15 Voyager Therapeutics, Inc.
10.15.1 Voyager Therapeutics, Inc. Company Information
10.15.2 Voyager Therapeutics, Inc. Introduction and Business Overview
10.15.3 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.15.4 Voyager Therapeutics, Inc. Spinal Muscular Atrophy Medicine Products Offered
10.15.5 Voyager Therapeutics, Inc. Recent Development
10.16 Vybion, Inc.
10.16.1 Vybion, Inc. Company Information
10.16.2 Vybion, Inc. Introduction and Business Overview
10.16.3 Vybion, Inc. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.16.4 Vybion, Inc. Spinal Muscular Atrophy Medicine Products Offered
10.16.5 Vybion, Inc. Recent Development
10.17 WAVE Life Sciences Ltd.
10.17.1 WAVE Life Sciences Ltd. Company Information
10.17.2 WAVE Life Sciences Ltd. Introduction and Business Overview
10.17.3 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Sales, Revenue and Gross Margin (2018-2023)
10.17.4 WAVE Life Sciences Ltd. Spinal Muscular Atrophy Medicine Products Offered
10.17.5 WAVE Life Sciences Ltd. Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Spinal Muscular Atrophy Medicine Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Spinal Muscular Atrophy Medicine Industrial Chain Analysis
11.4 Spinal Muscular Atrophy Medicine Market Dynamics
11.4.1 Spinal Muscular Atrophy Medicine Industry Trends
11.4.2 Spinal Muscular Atrophy Medicine Market Drivers
11.4.3 Spinal Muscular Atrophy Medicine Market Challenges
11.4.4 Spinal Muscular Atrophy Medicine Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Spinal Muscular Atrophy Medicine Distributors
12.3 Spinal Muscular Atrophy Medicine Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
